BiotechTube

Suramin Sodium

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autism Spectrum Disorder

Conditions

Autism Spectrum Disorder

Trial Timeline

Jun 1, 2019 → Mar 15, 2021

NCT ID
NCT06058962

About Suramin Sodium

Suramin Sodium is a phase 2 stage product being developed by PaxMedica for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT06058962. Target conditions include Autism Spectrum Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06058962Phase 2Completed

Competing Products

20 competing products in Autism Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
Ketamine + PlaceboRoivant SciencesPhase 1
30
Cord Tissue Mesenchymal Stromal CellsCryo-CellPhase 2
44
NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose groupShionogiPre-clinical
23
Lurasidone 20 mg daily + Lurasidone + PlaceboSumitomo PharmaPhase 3
77
Cariprazine + PlaceboAbbViePhase 3
77
CariprazineAbbViePhase 1
33
Omalizumab Injection [Xolair]NovartisPhase 1
33
RO7017773RochePhase 1
33
Placebo + RO7017773RochePhase 2
52
BalovaptanRochePhase 1
33
BalovaptanRochePhase 1
33
Balovaptan + EsomeprazoleRochePhase 1
33
Placebo + RG7314RochePhase 2
52
Placebo + RO5285119RochePhase 2
52
Balovaptan + PlaceboRochePhase 3
77
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
76
AripiprazoleBristol Myers SquibbPhase 2
51
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
76
Brexpiprazole + PlaceboLundbeckPhase 3
74
BrexpiprazoleLundbeckPhase 3
74